Frangou Sophia, Donaldson Stuart, Hadjulis Michael, Landau Sabine, Goldstein Laura H
Section of Neurobiology of Psychosis, Institute of Psychiatry, PO66, Division of Psychological Medicine, De Crespigny Park, London, United Kingdom.
Biol Psychiatry. 2005 Dec 1;58(11):859-64. doi: 10.1016/j.biopsych.2005.04.056. Epub 2005 Jul 22.
Cognitive abnormalities are increasingly recognized as a feature of bipolar I disorder (BDI,) but there is limited information regarding the pattern and severity of cognitive impairment during remission and its relationship with clinical variables.
Forty-four remitted BDI patients recruited from a representative treatment sample and an equal number of matched healthy volunteers underwent comprehensive clinical and cognitive assessments. Cognitive evaluation covered the domains of IQ, memory, and executive function. The profile of cognitive deficits in patients was examined, and the correlation of executive function with clinical features and treatment variables was explored.
Remitted BDI patients were impaired in tests of executive function compared with healthy participants. Within the patient group, current antipsychotic treatment predicted worse performance across all executive function tests, whereas duration of illness predicted loss of inhibitory control. Residual mood symptoms, regardless of polarity, had a negative impact primarily on measures of attentional interference.
These results suggest that impaired executive function might be an important feature of BDI. Antipsychotic treatment, duration of illness, and level of symptoms are the most significant contributors to the observed impairment.
认知异常越来越被认为是双相I型障碍（BDI）的一个特征，但关于缓解期认知障碍的模式和严重程度及其与临床变量的关系的信息有限。
从一个具有代表性的治疗样本中招募了44名缓解期BDI患者，并招募了同等数量匹配的健康志愿者，对他们进行全面的临床和认知评估。认知评估涵盖智商、记忆和执行功能等领域。检查了患者认知缺陷的概况，并探讨了执行功能与临床特征和治疗变量之间的相关性。
与健康参与者相比，缓解期BDI患者在执行功能测试中存在损害。在患者组中，当前使用抗精神病药物治疗预示着在所有执行功能测试中表现更差，而病程预示着抑制控制能力的丧失。残留情绪症状，无论其极性如何，主要对注意力干扰测量有负面影响。
这些结果表明，执行功能受损可能是BDI的一个重要特征。抗精神病药物治疗、病程和症状水平是观察到的损害的最重要因素。
